跳至主要内容
临床试验/NCT00858650
NCT00858650已完成不适用

Registry of Hypogonadism in Men

Carelon Research25 个研究点 分布在 6 个国家目标入组 999 人开始时间: 2009年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
999
试验地点
25
主要终点
Prostate Cancer

研究概览

简要总结

The primary objective of the Registry of HYpogonadism in MEn (RHYME) is to establish and maintain a large, multi-national prospective registry of male patients who have been diagnosed with male hypogonadism (HG), also known as androgen deficiency or testosterone deficiency.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Male patients aged 18 years and older.
  • Diagnosis of hypogonadism including Klinefelter's or late onset HG. Patients may have been diagnosed at any point in their lives. Documentation of the diagnosis of HG (including symptomatology and laboratory values including testosterone levels confirmed on two separate occasions) is required.
  • Written informed consent.

排除标准

  • Any previous treatment with testosterone therapy.
  • History of breast cancer, prostate cancer, or high-grade prostatic intraepithelial neoplasia.
  • Prior radical prostatectomy.
  • Life expectancy shorter than 24 months as judged by the Clinical Site investigator.
  • Current major psychiatric disorders or drug or alcohol abuse, which will likely affect participation or compliance in the Registry, in the opinion of the Clinical Site Investigator.
  • Gender dysphoria or sexual reassignment (e.g., transexualism).
  • Patients actively enrolled in any interventional clinical trial.
  • Planned relocation outside Clinical Site region within 24 months.

结局指标

主要结局

Prostate Cancer

时间窗: 2-years

次要结局

  • Physical Health and Cardiovascular Outcome Measures(3-years)
  • PSA, IPSS, and Other Urologic Outcomes(3-years)
  • Sexual Function and Hypogonadism Symptoms(3-years)

研究者

发起方
Carelon Research
申办方类型
Other
责任方
Sponsor

研究点 (25)

Loading locations...

相似试验